OnDemand: January 2026 Grand Rounds - MASLD in Obesity: Not All Fat Was Created Equal-MASLD in Obesity

Video Transcription

Video Summary

Dr. Fernando Bril presented a lecture on metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as fatty liver disease, emphasizing that “not all fat was created equal.” He explained that MASLD is a systemic, insulin-resistant condition rooted in dysfunctional adipose tissue, leading to fat accumulation in the liver and other organs. He distinguished MASLD from MASH, the more severe inflammatory form, and highlighted fibrosis staging, especially F2–F3 (“at-risk MASH”), which is the key treatment target.<br /><br />He stressed that MASLD is highly prevalent, especially in obesity and type 2 diabetes, and is worsening over time. Because patients with advanced fibrosis often die from cardiovascular disease rather than liver failure, management must also aggressively address blood pressure, lipids, glucose, and weight.<br /><br />For screening, he recommended FIB-4 as the initial test, followed by confirmatory testing such as FibroScan/VCTE, ELF, or MRE if results are elevated. He noted limitations of FIB-4 in younger patients and certain populations. Treatment focuses on weight loss, cardiometabolic risk reduction, and medications with evidence for MASH, including semaglutide and resmetirom, with other therapies in development.

Keywords

MASLD

MASH

fibrosis staging

FIB-4

FibroScan

type 2 diabetes

obesity

semaglutide

resmetirom